Anindita Das, M.S., Ph.D.
Research program member: Cancer Molecular Genetics
1101 E. Marshall St.
Richmond, VA 23298-5048
Associate Professor, Internal Medicine, School of Medicine
PhD, University of Jadavpur, India (1997)
MS, University of Kalyani, India (1988)
I am interested in developing novel therapeutics that could selectively inhibit doxorubicin-induced cardiotoxicity but not tumoricidal activity. Previously, we showed that treatment with sildenafil and tadalafil (specific inhibitors of phosphodiesterase 5) prior to doxorubicin-treatment prevented cardiomyocyte apoptosis and improved cardiac function in the animals. Pre-clinical studies from our laboratory suggested that co-treatment with sildenafil potentiates antitumor efficacy of doxorubicin, while ameliorated doxorubicin-induced cardiotoxicity. Similarly, rapamycin, a selective inhibitor of mTOR, has been shown to protect against myocardial infarction and heart failure. mTORC1 signaling is hyperactive in the majority of cancers. Thus, inhibiting mTORC1 signaling has attracted great attention as an anti-cancer therapy. Considering the potent cardioprotective effects of sildenafil and rapamycin, we are interested in investigating the effect of combination treatment with these drugs whether these would protect heart against doxorubicin-induced cardiotoxicity while enhancing its antitumor activity.
Cardiotoxicity, myocardial ischemia/reperfusion, mTOR, PDE5, miRNA